A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Pfizer
Alterome Therapeutics, Inc.
Pfizer
Roswell Park Cancer Institute
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Institut du Cancer de Montpellier - Val d'Aurelle
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AIO-Studien-gGmbH
Mirati Therapeutics Inc.
Institut Bergonié
Pfizer
TheraOp
NuCana plc
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mirati Therapeutics Inc.
Alliance for Clinical Trials in Oncology
Al-Azhar University
Qilu Hospital of Shandong University
West China Hospital
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Hôpital Franco-Britannique-Fondation Cognacq-Jay
Shanghai Zhongshan Hospital
Amgen
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hadassah Medical Organization
SCRI Development Innovations, LLC
ChineseAMS
Medical Research Council
Fox Chase Cancer Center
Federation Francophone de Cancerologie Digestive
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Pfizer
Eli Lilly and Company
Alliance for Clinical Trials in Oncology